Top

Aspirin Colon Cancer

November 1, 2011 by · Comments Off on Aspirin Colon Cancer 

Aspirin Colon Cancer, Taking an aspirin every day has been recommended for people at high risk of an inherited form of bowel cancer. The findings, published in the journal The Lancet suggests the risk for people with Lynch syndrome could be reduced by 63 percent.

Professor Sir John Burn, Newcastle University, who led the study, told the BBC that the evidence “seems overwhelmingly strong.”

A daily dose of aspirin is prescribed to people at risk of heart attack or stroke, and some researchers have observed that these groups showed lower rates of colorectal cancer. The colorectal adenoma / carcinoma Prevention Programme (CAPP2) study – the first double-blind, randomized controlled trial of aspirin focuses on cancer prevention – confirmed that could have a dramatic effect on the development of colorectal tumors.

“People who have a clear family history, including bowel cancer should seriously consider adding low doses of aspirin to your routine and in particular those who have a genetic predisposition,” the teacher should record.

Lynch syndrome or hereditary nonpolyposis colorectal cancer (HNPCC) is an inherited form of colorectal cancer caused by genetic mutations, one in 1,000 people are carriers. About 90 percent of men and 70 percent of women with HNPCC develop colon cancer at age 70. They are also at risk of other cancers, including uterine, ovarian, breast, prostate, brain, pancreas, gall bladder, ureter, stomach and kidney.

Participants in the trial taking 600 mg CAPP2 aspirin or placebo daily between 1999 and 2005. The 861 patients were followed for up to ten years in 43 centers in 16 countries.

The 2007 data showed no difference between the two groups, but an evaluation in 2010 showed that while 34 people had developed new cases of colorectal cancer in the placebo group, there were only 19 new cases of cancer in the group treated with aspirin. Furthermore, we found that there was an overall reduction in other types of cancer – 23 in the placebo group and 10 in the group treated only with aspirin.

Based on these results, giving aspirin to people at risk could prevent up to 10,000 kinds of cancer over the next decade, which could save up to 1,000 lives. As people in the study who took aspirin showed no more side effects than those taking placebo, this could be a safe and cost effective to prevent cancer.

Taking aspirin is not without risks, which can increase the risk of ulcers and bleeding in the gut of some people, but, as Professor Burn said: “If we can prevent 10,000 cases of cancer in 1000 in exchange for ulcers and 100 strokes, in most people’s minds is a good business. ”

It is unclear exactly how aspirin – may be through its role as an inhibitor of COX2, which could act to kill the cells in the early stages of cancer, or even by the destruction of stem cells that can differentiate into cancer cells.

Further work will CAPP3 as a study to optimize the dose and duration of aspirin treatment.

Bottom